Holen Sie sich die Stockscreener-App
66.20
1.55%
1.01
Handel nachbörslich:
65.65
-0.55
-0.83%
Schlusskurs vom Vortag:
$65.19
Offen:
$65.98
24-Stunden-Volumen:
2.74M
Relative Volume:
1.33
Marktkapitalisierung:
$7.74B
Einnahmen:
$947.36M
Nettoeinkommen (Verlust:
$392.47M
KGV:
21.92
EPS:
3.02
Netto-Cashflow:
$392.71M
1W Leistung:
+0.53%
1M Leistung:
-4.03%
6M Leistung:
+8.19%
1J Leistung:
+15.84%
1-Tages-Spanne:
$64.72
$66.38
1-Wochen-Bereich:
$63.84
$66.97
52-Wochen-Spanne:
$42.01
$79.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Firmenname
Halozyme Therapeutics Inc
Sektor
Branche
Telefon
(858) 794-8889
Adresse
12390 EL CAMINO REAL, SAN DIEGO, CA
Vergleichen Sie HALO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
66.20 | 7.63B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-14 | Hochstufung | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-05-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Herabstufung | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Eingeleitet | TD Cowen | Outperform |
| 2023-07-24 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Berenberg | Buy |
| 2023-03-16 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Eingeleitet | Evercore ISI | Outperform |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Bestätigt | The Benchmark Company | Buy |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-01 | Eingeleitet | The Benchmark Company | Buy |
| 2020-02-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Fortgesetzt | Piper Jaffray | Neutral |
| 2018-05-11 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2017-10-16 | Bestätigt | Piper Jaffray | Overweight |
| 2017-01-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-11-18 | Eingeleitet | Citigroup | Buy |
| 2015-09-22 | Eingeleitet | Barclays | Overweight |
| 2015-06-22 | Bestätigt | JP Morgan | Overweight |
| 2015-03-03 | Bestätigt | UBS | Buy |
| 2015-02-18 | Bestätigt | MLV & Co | Buy |
| 2015-01-08 | Bestätigt | MLV & Co | Buy |
Alle ansehen
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
Halozyme Therapeutics (HALO) Reports Record Q3 Revenue Growth - GuruFocus
Transcript : Halozyme Therapeutics, Inc., Q3 2025 Earnings Call, Nov 03, 2025 - MarketScreener
Halozyme Q3 2025 slides: royalty revenue surges 52%, guidance raised on strong growth - Investing.com
Earnings call transcript: Halozyme Q3 2025 beats earnings expectations - Investing.com
Halozyme Rides Strong Royalty Growth To Lift Its Outlook - Finimize
Halozyme Therapeutics: Q3 Earnings Snapshot - KVUE
HALO Boosts 2025 Revenue Forecast Amid Strong Earnings Outlook - GuruFocus
Halozyme Raises 2025 Guidance After Strong Q3 Results - TipRanks
Halozyme Therapeutics, Inc. Q3 Profit Increases, Beats Estimates - Nasdaq
HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS - PR Newswire
Can Halozyme Therapeutics Inc. stock continue upward trendJuly 2025 Market Mood & Risk Managed Investment Strategies - newser.com
What insider trading reveals about Halozyme Therapeutics Inc. stockTrade Entry Report & Entry Point Strategy Guides - newser.com
Is Halozyme Therapeutics Inc. (RV7) stock dividend growth reliable2025 AllTime Highs & Daily Volume Surge Signals - newser.com
Strategies to average down on Halozyme Therapeutics Inc.Market Trend Report & Verified Stock Trade Ideas - newser.com
Tools to assess Halozyme Therapeutics Inc.’s risk profileJuly 2025 Patterns & Safe Entry Momentum Tips - newser.com
Exit strategy if you’re trapped in Halozyme Therapeutics Inc.Exit Point & AI Powered Buy/Sell Recommendations - newser.com
Will Halozyme Therapeutics Inc. (RV7) stock outperform global peersPortfolio Update Summary & Stepwise Swing Trade Plans - newser.com
Torray Investment Partners LLC Has $2.08 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Why Halozyme Therapeutics Inc. stock is in analyst buy zone2025 AllTime Highs & Intraday High Probability Alerts - newser.com
How Halozyme Therapeutics Inc. (RV7) stock reacts to stronger dollarBreakout Watch & AI Based Buy/Sell Signal Reports - newser.com
Why Halozyme Therapeutics Inc. stock could be next big winner2025 Momentum Check & Safe Capital Preservation Plans - newser.com
Assetmark Inc. Raises Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Arkadios Wealth Advisors Acquires 11,457 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Will Halozyme Therapeutics Inc. stock benefit from infrastructure spendingIPO Watch & Risk Managed Investment Strategies - newser.com
Will Halozyme Therapeutics Inc. price bounce be sustainableJuly 2025 Closing Moves & Free Low Drawdown Momentum Trade Ideas - newser.com
Will Halozyme Therapeutics Inc. stock benefit from upcoming earnings reportsQuarterly Portfolio Review & AI Driven Price Predictions - newser.com
Using Python tools to backtest Halozyme Therapeutics Inc. strategiesWeekly Trend Recap & Technical Pattern Based Signals - newser.com
Halozyme Therapeutics (HALO) Anticipates Strong Q3 Earnings Grow - GuruFocus
Will Halozyme Therapeutics Inc. stock see PE expansionMarket Activity Report & High Accuracy Investment Signals - newser.com
Combining price and volume data for Halozyme Therapeutics Inc.2025 Price Targets & Low Risk Entry Point Tips - newser.com
Retirement Systems of Alabama Sells 4,246 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
AlphaQuest LLC Purchases 5,133 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
HALOZYME THERAPEUTICS Earnings Preview: Recent $HALO Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Halozyme Therapeutics, Inc. $HALO Stock Position Lowered by Hantz Financial Services Inc. - MarketBeat
Backtesting results for Halozyme Therapeutics Inc. trading strategies2025 Fundamental Recap & AI Driven Stock Reports - newser.com
Finanzdaten der Halozyme Therapeutics Inc-Aktie (HALO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):